Clinical Trial Update: A Study of XZP-3621 in Chinese Patients With ALK Positive NSCLC [Phase 2]

View source ↗

Summary

Phase 2 study of XZP-3621 in ALK-positive non-small cell lung cancer is ongoing with no results yet available.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• XZP-3621

Snippet

Sponsor: Xuanzhu Biopharmaceutical Co., Ltd. | Conditions: ALK-positive NSCLC | Phase 2 | Status: UNKNOWN